The New England journal of medicine
-
Daratumumab, a human IgG1κ monoclonal antibody targeting CD38, is used to treat multiple myeloma. We describe successful treatment with daratumumab in a case of treatment-refractory pure red-cell aplasia after ABO-mismatched allogeneic stem-cell transplantation. ⋯ Standard treatments had no effect. Within 1 week after the initiation of treatment with daratumumab, he no longer required transfusions.
-
Editorial Comment
Advancing toward the Elimination of Lymphatic Filariasis.